Navigation Links
Drug-Coated Stents No Riskier in Long Run Than Bare Metal Ones
Date:11/4/2007

Largest study to date finds no difference in heart attack or mortality rates

SUNDAY, Nov. 4 (HealthDay News) -- In the largest study of its kind to date, Harvard researchers report that they have found drug-eluting stents pose no more risk of heart attack or death than bare metal stents do.

"There has been a long debate about the safety of drug-eluting stents," said lead investigator Dr. Laura Mauri, an assistant professor of medicine at Harvard Medical School and Brigham & Women's Hospital, in Boston. "It was very reassuring to see that there was not an increased rate of death or heart attack."

Mauri presented the findings during a news conference Sunday at the American Heart Association annual meeting in Orlando, Fla.

People who have blocked heart arteries often undergo a procedure called angioplasty, or percutaneous coronary intervention (PCI). A small tube called a catheter is inserted into the blood vessel, then a balloon on the tip of the catheter is inflated to open the blockage and restore blood flow. Typically, a stent, or tiny wire scaffold, is also inserted to keep the vessel open. However, stents carry the risk of blood clots forming within them -- a potentially dangerous condition called stent thrombosis.

It's clear that drug-eluting stents reduce the probability that a patient will need to undergo a repeat procedure within a year. However, there has been heightened concern in the medical community in the past year that coated stents seem to raise the risk of thrombosis.

"Drug-eluting stets reduced the need for revascularization procedures," Mauri said. "What's not clear is what are the long-term consequences of placing a drug-eluting stent versus a bare metal stent in a general population."

This trial took advantage of a statewide registry of people undergoing PCI procedures in Massachusetts.

"In Massachusetts, all patients who undergo stenting procedures, but also bypass procedures, are reported to the state, and their clinical outcomes are monitored," she explained.

Between April 2003 and December 2004, researchers identified 20,654 patients who were listed in the registry.

Participants were enrolled in the trial over an 18-month period, scheduled to coincide with the introduction of drug-eluting stents to the market. All were followed for a minimum of two years after receiving a stent.

Overall, 35 percent of the patients received a bare metal stent and 65 percent received a drug-eluting stent. The study was not randomized, which meant that patients received one or the other based on clinical decisions made by their doctors.

There was no significant difference in the incidence of death or heart attack between the two groups. "If anything, there was a lower rate of mortality in the drug-eluting group as compared to the bare metal stents," Mauri reported.

Dr. Sidney Smith is past president of the American Heart Association and professor of medicine and director of the Center for Cardiovascular Science and Medicine at the University of North Carolina School of Medicine in Chapel Hill. He said the new "findings are similar to what came out in [a recent] Lancet meta-analysis.

"We're still trying to evaluate the data and we're applying more precise criteria," he added.

More information

For more on stents, visit the American Heart Association.



SOURCES: Sidney Smith, M.D, past president of the American Heart Association and professor of medicine and director of the Center for Cardiovascular Science and Medicine at the University of North Carolina School of Medicine, Chapel Hill; Nov. 4, 2007, news conference with Laura Mauri, M.D., assistant professor, medicine, Harvard Medical School and Brigham and Women's Hospital, Boston; American Heart Association annual meeting, Orlando, Fla.


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Drug-Coated Stent
2. Failure of Drug-Coated Stent
3. Stronger Backing for Drug-Coated Stents
4. Drug-Coated Stents – Proven to be More Effectiv
5. Drug-Coated Stents Work Better In Diabetic Patients After Angioplasty
6. Drug-coated heart stents under scrutiny, after study
7. Off-label and Untested Use of Drug-coated Stents Appears Widespread
8. Studies Reveal Inappropriate Use Of Drug-Coated Stents
9. Expandable metal stents used in digestive cancers
10. The Efficacy Of Newer Stents Questioned
11. Analyzing The Side Effects Of Sirolimus Stents
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug-Coated Stents No Riskier in Long Run Than Bare Metal Ones
(Date:4/29/2016)... ... April 29, 2016 , ... Intellitec Solutions is ... of Microsoft Dynamics GP for one their long-term care clients. Working together with ... GP with key clinical management systems, and delivered a fully integrated accounting and ...
(Date:4/29/2016)... ... 29, 2016 , ... The number of chronically and seriously ill individuals is ... is an urgent need for highly skilled care managers and care coordinators. ... to train and retain care managers, and enhance their skills. , Care ...
(Date:4/28/2016)... ... April 28, 2016 , ... The Dentists Insurance Company ... signed a letter of intent with Moda to acquire Dentists Benefits ... , Started by dentists 36 years ago, TDIC focuses exclusively on supporting the ...
(Date:4/28/2016)... ... April 28, 2016 , ... Head Over Heels Athletic Arts’ gymnast, Brooklyn Varize, ... will be held at the University of Montana on April 28-May 1. Varize will ... River. , In order to qualify, Varize needed to place top seven all-around in ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... for Tobacco-Free Kids, a leading force in the fight to reduce tobacco use ... local policies that can help reduce tobacco use. The initiative brings together two ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)...  While Abbott,s announced purchase of St. Jude ... and stent business, healthcare research firm Kalorama Information ... into patient monitoring.  Kalorama said that patient monitoring ... with double-digit growth expected the next 5 years, ... Patient Monitoring . Abbott Laboratories agreed to ...
(Date:4/28/2016)...  The blood testing market in China ... Information and The Freedonia Group in a recent report.  ... The healthcare research firm said that China ... stations and in improving testing at the provincial level.  ... Blood Testing Market in China , which ...
(Date:4/28/2016)... JERUSALEM , April 28, 2016 ... ), a clinical-stage pharmaceutical company focused on the development of ... participate in the upcoming PIONEERS 2016 conference, presented by ... 5, 2016 in New York . ... overview at the conference. Presentation Details:   ...
Breaking Medicine Technology: